ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1063

Dysfunction of Natural Killer and Natural Killer T Cells in Patients with Adult Onset Still’s Disease

Young-Nan Cho1, Sung-Ji Lee1, Tae-Jong Kim2, Hye-Mi Jin1, Dong-Jin Park2, Seung-Jung Kee3 and Yong-Wook Park1, 1Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, 2Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, 3Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adult-onset Still's disease, functions and natural killer (NK) cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Adult onset Still’s disease (AOSD) is an uncommon systemic inflammatory disorder of unknown etiology. Natural killer (NK) cell dysfunction is frequently observed in some human autoimmune disease, such as systemic lupus erythematosus and rheumatoid arthritis. However, NK cell function has not previously been investigated in AOSD. Furthermore, the relation between NK and NKT cells has not been determined. Purpose of this study is to examine the levels and functions of NK and NKT cells, to investigate relationships between NK and NKT cells, and to determine the clinical relevance of NKT cell levels in patients with AOSD.

Methods: Patients with active untreated AOSD (n = 25) and age- and sex-matched healthy controls (n = 25) were enrolled in the study. NK and NKT cell levels were measured by flow cytometry. Peripheral blood mononuclear cells were cultured in vitro with α-galactosylceramide (α-GalCer). NK cytotoxicities against K562 cells and proliferation indices of NKT cells were estimated by flow cytometry.

Results: Percentages and absolute numbers of NKT cells were significantly lower in the peripheral blood of patients than in healthy controls. Proliferative responses of NKT cells to α-GalCer were also lower in patients, and this was found to be due to proinflammatory cytokines and NKT cell apoptosis. In addition, NK cytotoxicities were found to be significantly lower in patients than in healthy controls, but NK cell levels were comparable in the two groups. Notably, this NKT cell deficiency was found to be correlated with NK cell dysfunction and to reflect an active disease status. Furthermore, α-GalCer-mediated NK cytotoxicity, showing the interaction between NK and NKT cells, was significantly lower in patients than in healthy controls.

Conclusion:

Our findings show that NKT cells are numerically and functionally deficient in AOSD. In addition, we report a novel observation that NK cell dysfunction is related to NKT cell deficiency. These findings provide important information concerning the pathogenesis of AOSD.


Disclosure:

Y. N. Cho,
None;

S. J. Lee,
None;

T. J. Kim,
None;

H. M. Jin,
None;

D. J. Park,
None;

S. J. Kee,
None;

Y. W. Park,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dysfunction-of-natural-killer-and-natural-killer-t-cells-in-patients-with-adult-onset-stills-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology